Support & Resources

IPSEN CARES coverage, access, reimbursement, and education support logo

IPSEN CARES® patient support program can help you get access to your IQIRVO® prescription with the information and support you need.

To learn more about IPSEN CARES:

(866) 435-5677

Monday-Friday, 8:00 AM – 8:00 PM ET

Downloadable resources

IQIRVO Brochure

An informational brochure to help you understand the transformative power of IQIRVO

IQIRVO Discussion Guide

A guide to help you start the conversation about IQIRVO at your next appointment

Frequently Asked Questions


      IQIRVO is a once-daily oral pill used to treat primary biliary cholangitis (PBC) in adults.

        IQIRVO is indicated for adults with primary biliary cholangitis (PBC). IQIRVO is an add-on treatment, meaning it is taken alongside ursodiol. However, in people who are unable to take ursodiol, IQIRVO can be taken alone.

        Talk to your doctor to see if IQIRVO is right for you.

          IQIRVO is thought to act on multiple targets in the liver. Two of these targets are PPAR alpha and PPAR delta.* In the liver, PPAR alpha and PPAR delta help control liver inflammation and levels of certain substances, like bile acids.

          *This information is based on animal studies, and the way IQIRVO works is not fully understood.

            IQIRVO is taken once daily as an oral pill.

            IQIRVO can be taken with or without food.

            See your doctor for more specific dosing instructions and regimens.

              IQIRVO should be stored in its original packaging at room temperature. Keep IQIRVO out of reach of children.

                Talk to your doctor about starting IQIRVO. IPSEN CARES patient support program can help you get access to your IQIRVO prescription with the information and support you need. To learn more about IPSEN CARES, visit

                  Some people taking IQIRVO may be eligible for a $0 copay.a Learn more about financial assistance at

                    Learn about accessing IQIRVO at

                    Glossary of terms

                      Alkaline phosphatase, an enzyme found in the liver. High levels of ALP in the blood are associated with liver diseases like PBC. This marker can be used to track response to treatment.

                        A component of bile. High levels of bilirubin indicate advanced disease in PBC. Regular measurement of bilirubin can be used to track PBC disease progression and response to treatment.

                          Primary biliary cholangitis, a chronic autoimmune liver disease.

                            Peroxisome proliferator-activated receptor.

                              Ursodeoxycholic acid, also known as ursodiol. It is the standard first treatment option for people with PBC.

                                The upper limit of normal, or ULN, is the high end of a normal range for a lab value. When assessing a patient's response to treatment for PBC, the definition of response may include an ALP level in relation to the ULN (for example, an ALP level of 1.67 x ULN).

                                a Patient Eligibility & Terms and Conditions: Patients are not eligible for copay assistance through IPSEN CARES if they are enrolled in any state or federally funded programs for which drug prescriptions or coverage could be paid in part or in full, including, but not limited to, Medicare Part B, Medicare Part D, Medicaid, Medigap, VA, DoD, or TRICARE (collectively, “Government Programs”), or where prohibited by law. Patients must be United States residents (including its territories) and enrolled in IPSEN CARES to receive copay program benefits. Patients receiving assistance through another assistance program or foundation, free trial, or other similar offer or program, are not eligible for the copay assistance program during the current enrollment year. An annual calendar year maximum copay benefit applies. Patients may remain enrolled in copay assistance as long as eligibility criteria is met. Patients or guardians are responsible for reporting receipt of copay savings benefit to any insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled through the program, as may be required. Additionally, patients or guardians may not submit any benefit provided by this program for reimbursement through a Flexible Spending Account, Health Savings Account, Health Reimbursement Account, or otherwise to a government or private payor. Ipsen reserves the right to rescind, revoke, or amend these offers without notice at any time. Ipsen and/or its copay assistance vendor are not responsible for any transactions processed under this program where Medicaid, Medicare, or Medigap payment in part or full has been applied. Data related to patient participation may be collected, analyzed, and shared with Ipsen for market research and other purposes related to assessing the program. Data shared with Ipsen will be de-identified, meaning it will not identify the patient. Void outside of the United States and its territories or where prohibited by law, taxed, or restricted. This program is not health insurance. No other purchase is necessary. Copay assistance cannot be sold, purchased, traded, or counterfeited. Void if reproduced.

                                Indication and Important Safety Information

                                What is IQIRVO® used for?

                                IQIRVO is a prescription medicine used to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have not responded well to UDCA, or used alone in patients unable to tolerate UDCA.

                                IQIRVO is not recommended for use in people who have symptoms or signs of advanced liver disease. It is not known if taking IQIRVO will improve your chance of survival or prevent liver decompensation.

                                It is not known if IQIRVO is safe and effective in children under 18 years of age.

                                What Warnings should I know about IQIRVO?

                                • IQIRVO can cause muscle problems (myalgia, myopathy, rhabdomyolysis) and muscle pain that can be severe. Treatment with IQIRVO may cause muscle pain or worsen existing pain and can increase the level of an enzyme in your blood called creatine phosphokinase (CPK); both can be a sign of muscle damage. If there is new or worsening muscle pain, your healthcare provider may examine you and perform a blood test. Stop taking IQIRVO and call your healthcare provider right away if you have any of the following signs or symptoms: severe muscle pain, unexplained soreness, unexplained muscle weakness, or dark, reddish urine.
                                • IQIRVO may increase the risk of bone fractures. Tell your healthcare provider about any bone fractures, or if you develop pain, or have changes in your ability to move around.
                                • IQIRVO may cause harm to an unborn baby when taken during pregnancy. Women taking IQIRVO who can become pregnant should use effective birth control during treatment and for 3 weeks after the last dose of IQIRVO. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you may be pregnant.
                                • IQIRVO can cause liver problems and abnormal liver blood test results. Your healthcare provider should do tests before starting and during treatment with IQIRVO to check your liver function. Tell your healthcare provider right away if you experience any of the following during treatment with IQIRVO: swelling of your stomach-area (abdomen), yellowing of your skin or whites of your eyes, black, tarry, or bloody stools, mental changes such as confusion, being sleepier than usual or harder to wake up, slurred speech, mood swings, or changes in personality, or coughing up or vomiting blood, or your vomit looks like coffee grounds. If you have severe stomach-area (abdomen) pain, nausea, vomiting, diarrhea, loss of appetite or weight loss, new or worsening fatigue, weakness, fever and chills, light-headedness, or less frequent urination, tell your healthcare provider right away.
                                • Some people taking IQIRVO had allergic reactions, which may include rash, trouble breathing, itching, or swelling of your face, lips, tongue, or throat. If you experience any of these, stop taking IQIRVO, call your healthcare provider right away or go to the nearest hospital emergency room.
                                • IQIRVO can cause blockage of the bile duct and may increase your risk of gallstones. Call your healthcare provider right away if you develop pain in the upper right stomach area or yellowing of the skin.

                                You should not use IQIRVO if you:

                                • Have advanced liver disease.
                                • Are pregnant or plan to become pregnant. IQIRVO can harm your unborn baby. You should not become pregnant during treatment with IQIRVO.
                                • Are breastfeeding or plan to breastfeed. It is not known if IQIRVO passes into your breast milk. Talk with your healthcare provider about the best way to feed your baby if you take IQIRVO.

                                What are the side effects of IQIRVO?

                                The most common side effects of IQIRVO include weight gain, diarrhea, stomach pain, nausea, vomiting, joint pain, constipation, muscle pain, bone fractures, gastroesophageal reflux disease (GERD), dry mouth, weight loss, and rash. These are not all of the possible side effects of IQIRVO. Call your doctor for medical advice about side effects.

                                What other medications might interact with IQIRVO?

                                Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. IQIRVO can affect the way certain medicines work. Certain medicines may affect the way IQIRVO works. If you take a bile acid binding resin, take IQIRVO at least 4 hours before or after you take your bile acid resin.

                                You are encouraged to report side effects to FDA at 1-800-FDA-1088 or at You may also report side effects to Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127.

                                Please see full Prescribing Information.